如今的卡波西肉瘤与 40 年前已大不相同，不是吗？
Today's Kaposi sarcoma is not the same as it was 40 years ago, or is it?
机构信息
Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
J Med Virol. 2023 May;95(5):e28773. doi: 10.1002/jmv.28773.
Abstract
This review will provide an overview of the notion that Kaposi sarcoma (KS) is a disease that manifests under diverse and divergent circumstances. We begin with a historical introduction of KS and KS-associated herpesvirus (KSHV), highlight the diversity of clinical presentations of KS, summarize what we know about the cell of origin for this tumor, explore KSHV viral load as a potential biomarker for acute KSHV infections and KS-associated complications, and discuss immune modulators that impact KSHV infection, KSHV persistence, and KS disease.
摘要
这篇综述将概述卡波西肉瘤（KS）是一种在不同和不同情况下表现出来的疾病的概念。我们首先对 KS 和 KS 相关疱疹病毒（KSHV）进行历史介绍，强调 KS 的临床表现多样性，总结我们对这种肿瘤起源细胞的了解，探讨 KSHV 病毒载量作为急性 KSHV 感染和 KS 相关并发症的潜在生物标志物，并讨论影响 KSHV 感染、KSHV 持续存在和 KS 疾病的免疫调节剂。
相似文献
1
Today's Kaposi sarcoma is not the same as it was 40 years ago, or is it?
J Med Virol. 2023 May;95(5):e28773. doi: 10.1002/jmv.28773.
2
Kaposi sarcoma herpesvirus viral load in bronchoalveolar lavage as a diagnostic marker for pulmonary Kaposi sarcoma.
AIDS. 2024 Jul 1;38(8):1172-1180. doi: 10.1097/QAD.0000000000003897. Epub 2024 Apr 1.
3
Indicators for Increased Likelihood of Epidemic Kaposi Sarcoma Progression After Antiretroviral Therapy Initiation.
AIDS Res Hum Retroviruses. 2025 Jul;41(7):348-356. doi: 10.1089/aid.2025.0007. Epub 2025 Apr 3.
4
Genome evolution of Kaposi sarcoma-associated herpesvirus (KSHV).
J Virol. 2025 May 20;99(5):e0195024. doi: 10.1128/jvi.01950-24. Epub 2025 Apr 16.
5
Glycoproteins gM and gN are indispensable factors for rhesus macaque rhadinovirus replication and spread but can be reconstituted by KSHV chimeras.
J Virol. 2025 Mar 18;99(3):e0192224. doi: 10.1128/jvi.01922-24. Epub 2025 Feb 25.
6
Unraveling the Kaposi Sarcoma-Associated Herpesvirus (KSHV) Lifecycle: An Overview of Latency, Lytic Replication, and KSHV-Associated Diseases.
Viruses. 2025 Jan 26;17(2):177. doi: 10.3390/v17020177.
7
Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
mBio. 2018 May 8;9(3):e00756-18. doi: 10.1128/mBio.00756-18.
8
Kaposi Sarcoma-Associated Herpesvirus Sequencing in People Living With HIV in the Southern United States Reveals Subtype Diversity and Multiple Infections.
J Med Virol. 2025 Jul;97(7):e70467. doi: 10.1002/jmv.70467.
9
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.
Clin Cancer Res. 2022 Jun 13;28(12):2646-2656. doi: 10.1158/1078-0432.CCR-21-0645.
10
HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.
Clin Microbiol Rev. 2024 Sep 12;37(3):e0002223. doi: 10.1128/cmr.00022-23. Epub 2024 Jun 20.
引用本文的文献
1
Genome evolution of Kaposi sarcoma-associated herpesvirus (KSHV).
J Virol. 2025 May 20;99(5):e0195024. doi: 10.1128/jvi.01950-24. Epub 2025 Apr 16.
2
Integrative Functional Genomics Analysis of Kaposi Sarcoma Cohorts.
Res Sq. 2025 Mar 11:rs.3.rs-6146471. doi: 10.21203/rs.3.rs-6146471/v1.
3
The elevated expression of ORF75, a KSHV lytic gene, in Kaposi sarcoma lesions is driven by a GC-rich DNA cis element in its promoter region.
PLoS Pathog. 2025 Mar 17;21(3):e1012984. doi: 10.1371/journal.ppat.1012984. eCollection 2025 Mar.
4
Unraveling the Kaposi Sarcoma-Associated Herpesvirus (KSHV) Lifecycle: An Overview of Latency, Lytic Replication, and KSHV-Associated Diseases.
Viruses. 2025 Jan 26;17(2):177. doi: 10.3390/v17020177.
5
Mouse models of Kaposi sarcoma-associated herpesvirus (KSHV).
Virology. 2025 Feb;603:110384. doi: 10.1016/j.virol.2024.110384. Epub 2024 Dec 31.
6
KSHV ORF20 Promotes Coordinated Lytic Reactivation for Increased Infectious Particle Production.
Viruses. 2024 Sep 5;16(9):1418. doi: 10.3390/v16091418.
7
ORF48 is required for optimal lytic replication of Kaposi's sarcoma-associated herpesvirus.
PLoS Pathog. 2024 Aug 26;20(8):e1012081. doi: 10.1371/journal.ppat.1012081. eCollection 2024 Aug.
8
The complete Kaposi sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice.
Cell Host Microbe. 2024 May 8;32(5):755-767.e4. doi: 10.1016/j.chom.2024.03.012. Epub 2024 Apr 22.
9
Activation of glucocorticoid receptor signaling inhibits KSHV-induced inflammation and tumorigenesis.
mBio. 2024 Jan 16;15(1):e0301123. doi: 10.1128/mbio.03011-23. Epub 2023 Dec 20.
10
Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease.
JCI Insight. 2023 Nov 22;8(22):e167854. doi: 10.1172/jci.insight.167854.
本文引用的文献
1
KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi's sarcoma studies.
PLoS Pathog. 2023 Jan 23;19(1):e1010753. doi: 10.1371/journal.ppat.1010753. eCollection 2023 Jan.
2
KSHV-encoded ORF45 activates human NLRP1 inflammasome.
Nat Immunol. 2022 Jun;23(6):916-926. doi: 10.1038/s41590-022-01199-x. Epub 2022 May 26.
3
Years of life lost to cancer among the United States HIV population, 2006-2015.
AIDS. 2022 Jul 15;36(9):1279-1286. doi: 10.1097/QAD.0000000000003249. Epub 2022 May 25.
4
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).
Ann Oncol. 2022 Jul;33(7):720-727. doi: 10.1016/j.annonc.2022.03.012. Epub 2022 Mar 23.
5
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2022 Apr;23(4):491-500. doi: 10.1016/S1470-2045(22)00097-3. Epub 2022 Mar 10.
6
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.
Clin Cancer Res. 2022 Jun 13;28(12):2646-2656. doi: 10.1158/1078-0432.CCR-21-0645.
7
Evidence for Multiple Subpopulations of Herpesvirus-Latently Infected Cells.
mBio. 2022 Feb 22;13(1):e0347321. doi: 10.1128/mbio.03473-21. Epub 2022 Jan 4.
8
Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.
Sci Transl Med. 2022 Jan 26;14(629):eabl3836. doi: 10.1126/scitranslmed.abl3836.
9
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.
Clin Cancer Res. 2022 Mar 1;28(5):840-850. doi: 10.1158/1078-0432.CCR-21-3364.
10
Kaposi's sarcoma-associated herpesvirus promotes mesenchymal-to-endothelial transition by resolving the bivalent chromatin of PROX1 gene.
PLoS Pathog. 2021 Sep 7;17(9):e1009847. doi: 10.1371/journal.ppat.1009847. eCollection 2021 Sep.
Zotero 插件